Skip to main content
AprilBio Co.,Ltd. logo

AprilBio Co.,Ltd. — Investor Relations & Filings

Ticker · 397030 ISIN · KR7397030008 KO Professional, scientific and technical activities
Open in API
Filings indexed 152 across all filing types
Latest filing 2025-03-13 AGM Information
Country KR South Korea
Listing KO 397030

About AprilBio Co.,Ltd.

http://www.aprilbio.com/en/

AprilBio is a biotechnology company that develops innovative biologic drugs, including therapeutic antibodies and recombinant proteins. The company's core is its proprietary SAFA (anti-Serum Albumin Fab-Associated) platform technology, which utilizes an albumin-binding antibody fragment to create long-acting therapeutics. This platform is designed to enhance the efficacy, safety, and plasma half-life of drug candidates while minimizing adverse effects. AprilBio's research and development pipeline focuses on addressing unmet medical needs in therapeutic areas such as autoimmune diseases, oncology, and other inflammatory and rare diseases. The company advances new drug candidates through early clinical development stages for potential technology transfer.

Recent filings

Filing Released Lang Actions
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for AprilBio. It contains the meeting agenda, date, location, and detailed management information including board activities, remuneration, and business overview (Management Report/MDA section). While it contains management information, the primary purpose of this specific document is to formally notify shareholders of the upcoming Annual General Meeting (AGM) and provide the necessary materials for voting. In the context of financial filings, this is classified as a Proxy Solicitation & Information Statement (PSI) as it provides the information required for shareholders to vote on the agenda items listed.
2025-03-13 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) system titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of the audit opinion, key financial data, and confirmation of the auditor's report receipt. While it contains financial data, it is a standardized regulatory disclosure form announcing the completion and submission of the audit, rather than the full annual report document itself. Therefore, it fits the 'Report Publication Announcement' (RPA) category as it serves to notify the market of the availability of the audit results. FY 2024
2025-03-13 Korean
사업보고서 (2024.12)
Annual Report Classification · 100% confidence The document is a '사업보고서' (Business Report) for the 12th fiscal year (2024) of AprilBio Co., Ltd. It contains comprehensive financial information, business overview, management discussion, and corporate governance details, which are the standard components of a Korean 10-K equivalent (Annual Report). FY 2024
2025-03-13 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by AprilBio. It outlines the date, location, and agenda items for the upcoming Annual General Meeting, including the approval of financial statements, re-election of directors, and remuneration limits. This type of document is a standard proxy solicitation and information statement provided to shareholders to inform them of meeting details and agenda items, which falls under the Proxy Solicitation & Information Statement category.
2025-03-06 Korean
주주총회집중일개최사유신고
AGM Information Classification · 95% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company scheduled its AGM on a date that coincides with other companies' meetings, citing internal operational constraints. Since this is a specific regulatory disclosure required by the exchange and does not fit into categories like AGM-R (presentation materials) or PSI (proxy solicitation), it is best classified as a general regulatory filing.
2025-03-06 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is specifically used to report insider transactions or changes in share ownership by company directors and executives. According to the provided definitions, this falls under 'Director's Dealing' (DIRS).
2025-02-14 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.